Previous 10 | Next 10 |
JACKSON CENTER, PA / ACCESSWIRE / December 15, 2021 / Halberd Corporation (OTC PINK:HALB) has demonstrated 100% eradication of Interleukin-12 (IL-12) from synthetic cerebral spinal fluid (CSF) in preliminary testing. Interleukin-12 is a pro-inflammatory cytokine which has recently been ide...
JACKSON CENTER, PA / ACCESSWIRE / December 13, 2021 / Halberd Corporation (OTC PINK:HALB) has demonstrated 100% eradication of Interleukin-1 (IL-1) from synthetic cerebral spinal fluid (CSF) in preliminary testing. Interleukin-1 is associated with numerous diseases ranging from autoimmune ...
Jackson Center, Pennsylvania--(Newsfile Corp. - December 13, 2021) - Halberd Corporation (OTC Pink: HALB) has demonstrated 100% eradication of Interleukin-1 (IL-1) from synthetic cerebral spinal fluid (CSF) in preliminary testing. Interleukin-1 is associated with numerous diseases ranging from...
Jackson Center, Pennsylvania--(Newsfile Corp. - December 6, 2021) - Halberd Corporation (OTC PINK: HALB) completed verification tests on elimination of Tumor Necrosis Factor-alpha (TNF-alpha) from synthetic cerebral spinal fluid (CSF). These tests confirmed virtually 100% elimination of T...
JACKSON CENTER, PA / ACCESSWIRE / December 6, 2021 / Halberd Corporation (OTC PINK:HALB) completed verification tests on elimination of Tumor Necrosis Factor-alpha (TNF-alpha) from synthetic cerebral spinal fluid (CSF). These tests confirmed virtually 100% elimination of TNF-alpha through ...
JACKSON CENTER, PA / ACCESSWIRE / November 22, 2021 / Halberd Corporation (OTC PINK:HALB) successfully eradicated 85% of Tumor Necrosis Factor-alpha (TNF-α) from synthetic cerebral spinal fluid (CSF) in preliminary testing. Through Halberd's patented extracorporeal process, in combi...
Jackson Center, Pennsylvania--(Newsfile Corp. - November 22, 2021) - Halberd Corporation (OTC Pink: HALB) successfully eradicated 85% of Tumor Necrosis Factor-alpha (TNF-α) from synthetic cerebral spinal fluid (CSF) in preliminary testing. Through Halberd's patented extracorporeal proce...
Jackson Center, Pennsylvania--(Newsfile Corp. - November 8, 2021) - Halberd Corporation (OTC Pink: HALB) filed a non-provisional patent application for the extracorporeal treatment of Covid-19 through exposure to radio frequency waves. Previously, Halberd filed a provisional patent application...
LOS ANGELES CALIFORNIA, Nov. 02, 2021 (GLOBE NEWSWIRE) -- GTX Corp (OTC: GTXO) (“the Company”) , a pioneer in the fields of: health & safety wearable GPS human and asset tracking systems and personal protective medical equipment and supplies, today anno...
Elevated levels of IL-6 are believed to be causal factors in PTSD, Chronic Traumatic Encephalopathy, & Alzheimer's Disease. JACKSON CENTER, PA / ACCESSWIRE / November 1, 2021 / Halberd Corporation (OTC PINK:HALB) successfully eradicated 100% of IL-6 from synthetic cerebral spinal ...
News, Short Squeeze, Breakout and More Instantly...
Walt Disney once said, "All our dreams can come true if we have the courage to pursue them". JACKSON CENTER, PA / ACCESSWIRE / May 22, 2024 / Halberd Corporation (OTC PINK:HALB) in cooperation with Athena GTX, Inc is standing at the threshold of some major advancements to treat the issues ...
Daniel J. Harvey and Adam Lambert Improving Servicemember Transition to Reduce Veteran Suicide Act, passed the U.S. House unanimously. JACKSON CENTER, PA / ACCESSWIRE / May 9, 2024 / Halberd Corporation's (OTC PINK:HALB) two active programs for the treatment and mitigation of the negative ...
LDN+ Drug Designed to Combat PTSD and Suicidal Ideation JACKSON CENTER, PA / ACCESSWIRE / April 30, 2024 / Halberd Corporation (OTC PINK:HALB) announced a pre-pilot study of its patented LDN+ drug with military volunteers has now begun with limited participants but is currently expected to...